The burgeoning landscape of therapy for obesity and type 2 glucose intolerance is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant variations in their pharmacological profiles and clinical trial results are emerging. Retatrutide, bo… Read More

Arriving in the arena of weight management therapy, retatrutide is a different strategy. Beyond many available medications, retatrutide works as a double agonist, at once targeting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. The dual engagement promotes various helpful effects, including enhanced glucose … Read More